BridgeBio is significantly boosted its course of a innovative therapy for cardiac amyloidosis, utilizing Attruby. Initial clinical data reveals promising improvements for patients diagnosed with this severe condition. https://biotech039220.oblogation.com/40919680/company-improves-attr-cm-treatment-with-the-therapy